LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Simulations Plus Inc

Closed

SectorHealthcare

11.37 -6.42

Overview

Share price change

24h

Current

Min

11.11

Max

11.6

Key metrics

By Trading Economics

Income

1.4M

676K

Sales

961K

18M

P/E

Sector Avg

48.528

110.024

EPS

-0.034

Dividend yield

0.48

Profit margin

3.67

Employees

212

EBITDA

-3M

2.3M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+62.95% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.48%

2.26%

Next Earnings

2 kwi 2026

Market Stats

By TradingEconomics

Market Cap

-120M

248M

Previous open

17.79

Previous close

11.37

News Sentiment

By Acuity

50%

50%

149 / 351 Ranking in Healthcare

Simulations Plus Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 lut 2026, 22:36 UTC

Earnings

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 lut 2026, 22:32 UTC

Earnings

Woodside Energy Fiscal Year Net Profit Falls 24%

23 lut 2026, 23:58 UTC

Market Talk
Earnings

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 lut 2026, 23:58 UTC

Market Talk
Earnings

Global Energy Roundup: Market Talk

23 lut 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 lut 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 lut 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Crescent Capital Partners Owns 53% of ClearView Wealth

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 lut 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 lut 2026, 23:39 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 lut 2026, 23:31 UTC

Earnings

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 lut 2026, 23:31 UTC

Earnings

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 lut 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 lut 2026, 23:27 UTC

Earnings

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 lut 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 lut 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 lut 2026, 22:31 UTC

Earnings

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 lut 2026, 22:24 UTC

Earnings

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy FY Underlying Ebitda A$700.9 Million

23 lut 2026, 22:22 UTC

Earnings

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 lut 2026, 22:21 UTC

Earnings

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 lut 2026, 22:21 UTC

Earnings

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 lut 2026, 22:20 UTC

Earnings

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Peer Comparison

Price change

Simulations Plus Inc Forecast

Price Target

By TipRanks

62.95% upside

12 Months Forecast

Average 19 USD  62.95%

High 19 USD

Low 19 USD

Based on 4 Wall Street analysts offering 12 month price targets forSimulations Plus Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Sentiment

By Acuity

149 / 351 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat